Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2006 December; 7(4): E63–E69.
Published online 2014 March 30. doi:  10.1208/pt070491
PMCID: PMC2750328

Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A


The purpose of this research was to investigate novel particulate carrier system such as solid lipid nanoparticles (SLN) for topical application of vitamin A palmitate and to study its beneficial effects on skin. Topical gels enriched with SLN of vitamin A were prepared. The solid lipid nanoparticulate dispersion was prepared using high-pressure homogenization technique and was incorporated into polymeric gels of Carbopol, Pemulen, Lutrol, and Xanthan gum for convenient application. The nanoparticulate dispersion and its gels were evaluated for various parameters such as particle size, in vitro drug release, in vitro penetration, in vivo skin hydration, and skin irritation. The solid lipid nanoparticulate dispersion showed mean particle size of 350 nm. Differential scanning calorimetry studies revealed no drugexcipient incompatibility. In vitro release profile of vitamin A palmitate from nanoparticulate dispersion and its gel showed prolonged drug release up to 24 hours, which could be owing to embedment of drug in the solid lipid core. In vitro penetration studies showed almost 2 times higher drug concentration in the skin with lipid nanoparticle-enriched gel as compared with conventional gel, thus indicating better localization of the drug in the skin. In vivo skin hydration studies in albino rats revealed increase in the thickness of the stratum corneum with improved skin hydration. The developed formulation was nonirritant to the skin with no erythema or edema and had primary irritation index of 0.00. Thus it can be concluded that SLN represents a promising particulate carrier having controlled drug release, improved skin hydration, and potential to localize the drug in the skin with no skin irritation.

Keywords: Solid lipid nanoparticles, topical, gel, vitamin A

Full Text

The Full Text of this article is available as a PDF (299K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Utreja S, Jain NK. Solid lipid nanoparticles. In: Jain NK, editor. Advances in Controlled and Novel Drug Delivery. New Delhi, India: CBS Publishers; 2001. pp. 408–425.
2. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177. doi: 10.1016/S0939-6411(00)00087-4. [PubMed] [Cross Ref]
3. Vyas SP, Khar RK. Nanoparticles. In: Vyas SP, Khar RK, editors. Targeted and Controlled Drug Delivery—Novel Carrier Systems. New Delhi, India: CBS Publishers; 2002. pp. 331–386.
4. Jenning V, Gysler A, Schafer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49:211–218. doi: 10.1016/S0939-6411(99)00075-2. [PubMed] [Cross Ref]
5. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155. doi: 10.1016/S0169-409X(02)00118-7. [PubMed] [Cross Ref]
6. Desorgher M, Desorgher S. The Nutrient Needs of the Autist—Vitamin A. Autism, Pigments, and the Immune System. 2002. Available at: Accessed: November 3, 2006.
7. Government of India Ministry of Health and Family Welfare . Indian Pharmacopoeia 1996. Delhi, India: Controller of Publications; 1996. pp. A61–A62.
8. Thomas J, Schloemer B. Primary Skin Irritation Test in the Rabbit of Water Jel Burn Dressing. Available at: Accesed: July 20, 2004.
9. Jenning V, Hildebrand G, Gysler A, Muller R, Schafer-Korting M, Gohla S. Solid lipid nanoparticles (SLNTM) for topical application: occlusive properties. Proceedings of the 26th International Symposium of Controlled Release of Bioactive Materials; June 20–25, 1999; Boston, MA; 1999:405–406.
10. Wissing S, Craig D, Barker SA, Moore W. An investigation into the use of stepwise DSC as a means of detecting drug-excipient incompatibility. Int J Pharm. 2000;199:141–150. doi: 10.1016/S0378-5173(00)00380-X. [PubMed] [Cross Ref]
11. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47:125–132. doi: 10.1016/S0939-6411(98)00074-5. [PubMed] [Cross Ref]
12. Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs) Biomaterials. 2003;24:1781–1785. doi: 10.1016/S0142-9612(02)00578-1. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists